Spurred by important advances in biomedical research, Canadian health systems are on the cusp of a new era of precision medicine.

However, capturing the promise of precision medicine will only be possible if a wide range of partners - from policymakers and patient groups, to clinicians and innovators - can come together to accomplish three key goals: (1) Improve the reimbursement of genetic tests; (2) Optimize the use of RWE to reduce payer uncertainty and (3) Accelerate the development of Managed-Entry Agreements. How can we work together to achieve these shared objectives?

Watch the virtual discussion in English below.

Watch the the virtual discussion in French here.

Listen to the virtual discussion in podcast format here.

About CONECTed

CONECTed is a network of oncology patient leaders that are dedicated to developing evidence-based solutions that improve access to innovative oncology therapies and approaches that promote high-quality care and improved patient outcomes. With the ultimate goal of all cancer patients having access to cancer drugs regardless of socio-economic status, postal code or other barriers. 

Through policy shaping, solution building, and education, this network has been involved in addressing issues within the system, at the government level and in HTA both related to innovative medicines and other therapies. As new innovative medicines come to the Canadian market, questions of sustainability of our healthcare system as a whole continue to take precedence over the conversation.

Learn more about CONECTed here.